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Rhodium-catalyzed hydroboration has attracted much interest, 
in part owing to the complementary regio-and diastereoselec-
tivity obtained with certain substrates compared to the uncat-
alyzed process.[1, 2] The novel regiocontrol is exemplified in 
the rhodium-catalyzed hydroborations of vinyl arenes, which, 
in contrast to the uncatalyzed reaction, introduce boron at the 
benzylic position. For example, styrene affords 1-phenyleth-
anol after hydroboration and oxidation. Several catalyst sys-
tems exhibit both high regio-and enantioselectivity for the cat-
alytic asymmetric hydroboration of styrene and some of its 
substituted derivatives.[3] However, the reaction is sensitive 
to both steric and electronic factors, and for the reactions of 
ortho-substituted styrene derivatives, an important subclass 
ofthese substrates, high levels of enantioselection have proved 
elusive.[4] Herein, we report the use of self-assembled ligands 
(SALs) for the catalytic asymmetric hydroboration ofa family 
of ortho-substituted styrene derivatives varying in steric and 
electronic character.  
Several strategies for preparing novel ligands by self-
assembly have emerged as promising approaches to unsolved 
problems in catalysis.[5,6] We reported a novel method for 
the in situ preparation of chiral ligand libraries by chirality-
directed self-assembly, a strategy by which the topography at 
the catalytic site is varied over a wide range by subtle changes 
in the ligand scaffold.[7] 
Bifunctional subunits (S,S)- and (R,R)-1A–P exploit a chi-
ral bisoxazoline to direct the self-assembly, substituted with 
a series of phenylmethyl or biphenylmethyl tethers terminat-
ing in a phosphite ligating group derived from TADDOL[8] 
((4R,5R)-α,α,α′,α′-tetraphenyl-2,2-dimethyl-1,3dioxolan-4,5-
dimethanol, TDL). The subunits differ with respect to the 
tether substitution pattern (Table 1). 
A mixture of (S,S)-and (R,R)-1A–P readily undergoes chi-
rality-directed self-assembly upon addition of zinc(II) to yield 
the heterodimeric (SS,RR)-SALs.[9] In the present study, we 
found it convenient to first prepare the (S,S)- and (R,R) ho-
modimers from 1A–P, which upon mixing rapidly equilibrate 
to the (SS,RR)-heterodimer. For example, mixing [{(S,S)-
1D}2Zn] with [{(R,R)-1C}2Zn] affords (SS,RR)-SAL DC 
(Scheme 1). The latter can be isolated; however, the SALs 
and their derived catalyst systems are typically generated in 
situ and used without isolation.[10] Combining various pairs 
of (S,S)- and (R,R)-1A–P quickly affords a library of unique 
(SS,RR)-SAL XY differing only in scaffold structure. 
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Table 1: TADDOL-derived subunits (S,S)-and (R,R)-1A–P are used to 
form (SS,RR)-SAL XY by chirality-directed self-assembly. 
                        X = O          X = CH2O 
Ar2             1,3-Ar1     1,4-Ar1  Ar2       1,3-Ar1    1,4-Ar1 
—  A  B  —  I  J 
1,2- C  D  1,2- K  L 
1,3- E  F  1.3- M  N 
1,4- G  H  1,4- O  P
Scheme 1. Heterodimer (SS,RR)-SAL DC is readily prepared by ligand 
exchange of the appropriate homodimers.
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The hydroboration of 2-methoxystyrene (2a) with pinacol-
borane (PBH) was screened using [{Rh(nbd)Cl}2] (nbd = 2,5-
norbornadiene) in combination with 162 in situ prepared SAL 
XY [Eq. (1), DME = dimethoxyethane].[11] Remarkably, this 
readily accessible, focused ligand library affords R:S enantio-
meric ratios ranging from 98:2 to 35:65 (Figure 1).[12] Anal-
ysis of these data reveals that with few exceptions the most 
efficient catalysts combine SALs containing only phenyl phos-
phite subunits 1A–H (65 to 96% ee (R)). The SALs contain-
ing only benzyl phosphite subunits (1I–P) afford lower levels 
of enantioselectivity (30 % ee (S) to 40% ee (R)). Mixed phe-
nyl/benzyl combinations tend to fall in between. 
 
Varying the catalyst precursor reveals other remarkable 
features of the role of scaffold structure in catalyst optimiza-
tion. The nature of the RhI catalyst precursor can be an im-
portant factor in catalytic asymmetric hydroboration.[13] 
Having obtained data using [{Rh(nbd)Cl}2], the reaction of 
2-methoxystyrene (2a) was carried out using [Rh(nbd)2BF4] 
in combination with each of the 64 possible SALs from de-
rived from subunits 1A–H. As summarized in Table 2, differ-
ent optimal ligand scaffolds were found for each catalyst pre-
cursor. SAL DC (96% ee) was best for [{Rh(nbd)Cl}2] while 
SAL HC (95% ee) proved best for [Rh(nbd)2BF4]. It is inter-
esting to note that while subunit (R,R)-1C is present in both 
optimal SALs, the SAL combination containing only 1C (i.e., 
the pseudo-C2-symmetric SAL CC) is less effective with ei-
ther catalyst precursor. In addition, SAL DC is more selective 
than its closely related diastereomer SAL CD, and SAL HC is 
more selective than its corresponding diastereomer SAL CH. 
Prior studies have shown that the efficiency of rhodium-
catalyzed asymmetric hydroboration is quite sensitive to steric 
and electronic factors in the substrate.[14] The availability of 
a range of different SAL scaffolds proves useful for the rapid 
optimization of different catalysts for individual substrates. 
High regio- and enantioselectivity can be obtained for each 
substrate within the series of ortho-substituted styrene deriva-
tives 2a–e using in situ generated [(SAL XY)Rh(nbd)BF4] cat-
alysts derived from the subunits 1A–H.[15] The best results for 
each substrate are highlighted in Table 3 (entries in boldface); 
these results are for preparative reactions run on a 1-mmol 
or greater scale. The regio-and enantioselectivities found in 
preparative reactions are similar to those obtained under the 
screening conditions (± 1–2%); the yields of isolated product 
range from 82–98%. For comparison, Table 3 also gives the 
results achieved using two equivalents of (TDL)POPh (53–
81 % ee), the monodentate chiral phosphite moiety present in
Figure 1. Wide variation in enantioselectivity is observed for the SAL/
[{Rh(nbd)Cl}2]-catalyzed asymmetric hydroboration of 2-methoxysty-
rene (2a) as a function of ligand scaffold.
Table 2: {RhICl} and {RhIBF4} catalyst precursors require different li-
gand scaffolds for the hydroboration of 2-methoxystyrene (2a).[a] 
Ligand                                 [{Rh(nbd)Cl}2]                       [Rh(nbd)2BF4] 
SAL DC  96 (98)  78 (96) 
SAL HC  86 (94)  95 (98) 
SAL CC  75 (88)  84 (97) 
SAL CD  92 (94)  — 
SAL CH  —  86 (97) 
SAL DD  79 (90)  — 
SAL HH  —  93 (94) 
[a] Conditions: see Equation (1). The results listed indicate % ee (% 
α-isomer). 
Table 3: Different ligand scaffolds are used to achieve optimal results 
for substrates 2a–e with [(SAL XY)Rh(nbd)BF4] catalysts.[a] 
Ligand                   3a             3b                3c            3d            3e 
                  (R = OMe)    (R = Me)    (R = CF3)    (R= Cl)     (R= F) 
SAL HC  94 (99)[b] 87 (86) 66 (66) 78 (96) 76 (88)
SAL EE  66 (93)  91 (95)[b] 76 (49) 73 (87)  91 (92)[b]
SAL ED  75 (96) 85 (93) 91 (95)[b] 68 (67) 68 (78)
SAL HG  91 (95)  87 (81)  53 (72)  93 (92)[b]  77 (73) 
(TDL)POPh  81 (91) 73 (78) 69 (73) 77 (83) 53 (76)
literature[c]  82 (99)  92 (93)  83 (97)  69 (93)  72 (92) 
[a] Conditions: see Equation (1).The results indicate % ee (% α-isomer). 
[b] Reaction run on a 1-mmol scale. [c] The best results previously 
reported for each substrate; see reference [7] for details. 
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each SAL, as well as the best results previously reported for 
each substrate. For substrates 2a (R = OMe) and 2c–e (R = 
CF3, Cl, F), the SAL identified is the most selective catalyst 
reported to date. For 2b (R = Me), the best SAL and literature 
results are nearly equivalent. 
The importance of the heterodimeric zinc complex as a 
structural element for the SALs is further illustrated by com-
paring three diastereomeric ligands derived from (S,S)and 
(R,R)-1E. Even though the ligating groups and tethers are 
identical in all three zinc complexes, the results obtained in 
the hydroboration of 2-methylstyrene (2b) vary significantly. 
In contrast to the (SS,RR)-heterodimer, SAL EE (91% ee,95% 
α-3b), the diastereomeric (SS,SS)- and (RR,RR)-homodimers, 
that is, [{(S,S)-1E}2Zn] and [{(R,R)1E}2Zn], exhibit low reac-
tivity and lower selectivity: 87% ee (84% α-3b) and 79% ee 
(82 % α-3b), respectively. 
In summary, a series of TADDOL phosphite-bearing 
SALs, readily prepared in combinatorial arrays by chirality-
directed self-assembly, provides a focused ligand library for 
RhI-catalyzed hydroboration. These SALs exhibit the unique 
feature of achieving high enantioselectivity through the sub-
tle manipulation ofthe chiral catalytic pocket by small system-
atic changes in the ligand scaffold, an approach not available 
with classic ligand designs. The ligands differ only in scaf-
fold structure, yet the enantioselectivity obtained in catalytic 
asymmetric hydroboration of 2-methoxystyrene varies from 
96% ee favoring the R-configuration to 30 % ee favoring S. 
{RhICl} and {RhIBF4} catalyst precursors and different sub-
strates require different ligand scaffolds to achieve success. 
Nevertheless, {(SAL XY)RhI} catalysts afford high regiose-
lectivity (92–99% α3) and enantioselectivity (91–96% ee) 
across a series of ortho-substituted styrenes varying in elec-
tronic character and steric demand. Thus, a facile method of 
self-assembly is exploited to fine tune catalysts by ligand scaf-
fold optimization, improving substrate generality in a reaction 
that has thus far exhibited rather limited substrate scope. Stud-
ies directed toward understanding the structural basis for the 
wide variation in selectivity as a function of ligand scaffold 
(i.e. the structure–activity relationship of these ligands) are in 
progress. 
Experimental Section 
[(SAL HC)Rh(nbd)BF4]-catalyzed asymmetric hydroboration of 2-
methoxystyrene: A solution of [{(S,S)-1H}2Zn] (10.0 mg, 1.4 × 10–
2 mmol) and [{(R,R)-1C}2Zn] (10.0 mg, 1.4 × 10–2 mmol) in CH2Cl2 
(10 mL) was stirred at ambient temperature (10 min), and then a so-
lution of [Rh(nbd)2BF4] (9.7 mg, 2.6 × 10
–2 mmol) in CH2Cl2 (5 mL) 
was added. The resulting mixture was stirred at ambient tempera-
ture (0.5 h), after which the volatile solvent was removed under vac-
uum. The residue was dissolved in DME (10 mL), stirred (0.5 h), and 
then a solution of 2-methoxystyrene (2a, 174.0 mg, 1.30 mmol) in 
DME (2.0 mL) and powdered 4-Å molecular sieves (ca. 0.5 g) were 
added. The resulting mixture was cooled (0 °C) and a solution of pi-
nacolborane (199.0 mg, 1.56 mmol) in DME (4.0 mL) added drop-
wise. The reaction mixture was gradually warmed to room tempera-
ture and stirred (12 h). Afterwards, the mixture was again cooled (0 
°C) and quenched by the addition of MeOH (10 mL), NaOH(aq) (3.0 
m, 15 mL), and H2O2 (aq) (1 mL of a 30% solution). The ice bath 
was removed, and the resulting mixture stirred (3 h, RT) and then fil-
tered. The filtrate was extracted with diethyl ether (3 × 15 mL) and 
the combined organics were dried (anhydrous Na2SO4), filtered, and 
concentrated. Chromatography on silica (10% 1:9 EtOAc/Hex) gives 
1-(2-methoxyphenyl)ethanol (3a, 194 mg, 98%) as a clear oil: cap-
illary GC analysis (J&W Scientific 30m × 0.25mm ID Cyclosil β, 
120  °C (1 min hold) to 130° at 18 min–1 then to 165° at 28 min–1) 
found peaks at 21.19 (97.2%, (R)-3a) and 23.55 (2.8%, (S)-3a); 1H 
NMR (400 MHz, CDCl3): δ =7.39 (1H, dd, J =7.5, 1.4 Hz), 7.37–
7.26 (1H, dt, J =8.2, 1.6 Hz), 7.00 (1 H, t, J =7.5 Hz), 6.90 (1 H, d, J 
=8.2 Hz), 5.15–5.11 (1H, q, J =13.0, 6.5 Hz), 3.88 (3H, s) 1.53 ppm 
(3H, d, J =6.5 Hz); 13C NMR (100 MHz, CDCl3): δ = 156.5, 133.6, 
128.2, 126.1, 120.8, 110.4, 66.4, 55.3, 23.0 ppm; [α]D
25   = +25.8° (c 
=1.4 g(100mL)–1, CHCl3). 
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All reactions are carried out under an atmosphere of dry nitrogen and use dry, degassed solvents 
unless noted otherwise. All solvents, 2-susbtituted styrene derivatives, PCl3 (99.999%), and 
pinacolborane were obtained from Aldrich Chemicals and used without further purification. For 
the hydroboration reaction, DME (Aldrich) was stored over activated 4A sieves and used without 
further purification. THF was distilled from sodium/benzophenone prior to use. [Rh(cod)Cl]2 
was purchased from Strem Chemicals, Inc. Rh(nbd)2BF4 was purchased from Alfa Aesar. NMR 
spectra were recorded on 300 or 400 MHz Bruker Avance NMR spectrometers.  
 
The syntheses of (R,R)- and (S,S)-1A-H follow the route illustrated by the preparation of the 
homodimer [(R,R)-1C]2Zn via the following scheme. 
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a) 4% Pd(OAc)2, 3.0 equiv. K2CO3, 1:1 DMF:H2O, RT 5 h.  b) 1.1 equiv. TBDPSCl, 4.0 equiv. imidazole, DMF, 0oC to RT, 12 h.  c) 1) 
1.0 equiv. NaHMDS, THF, -78 oC, 2 h, 2) 1.0 equiv. C(III), -78 oC to RT, 12h.  d) 1.0 equiv. TBAF, THF, RT, 10 h.  e) 1.2 equiv. 
(R)-C(VI), 20 equiv. TEA, 5% DMAP, THF, RT, 12h.  f) 1.0 equiv. Zn(OAc)2, 1:1 DCM:MeOH, RT, 5 min. 
 
 
4%  Pd(OAc)2
3.0 equiv. K2CO3
50% DMF in H2O
RT, 5 hrs
+
Me
B
I
OH
OH
OH
Me HO
C(I)  
 
a. Preparation of C(I) (adapted from the procedure of Cowart, et al.)1.  To a 500 mL 
round-bottom flask was added 2-iodophenol (11.0 g, 50.0 mmol), 3-toluyl boronic acid (7.48 g, 
55.0 mmol), and palladium acetate (0.455 g, 2.03 mmol). The mixture was dissolved in DMF 
(150 mL) and stirred at room temperature.  Potassium carbonate (20.7 g, 150 mmol) was 
dissolved in 150 mL of degassed water, and then added via cannula transfer.  The resulting 
mixture was stirred at room temperature (5 h).  Afterwards, the mixture was extracted ethyl 
acetate (3 x 100 mL) and the combined organic layers dried (anhydrous magnesium sulfate) and 
concentrated via rotovap.  The residue was chromatographed on flash silica (ca 150 g, 10 % 
ethyl acetate in hexanes) giving C(I) (8.90 g, 96 %) as clear oil: 1H NMR (400 MHz, CDCl3) δ 
7.44-7.35 (1H, m), 7.32-7.25 (5H, m), 7.05-7.00 (2H, m), 2.46 ppm (3H, s); 13C NMR (100 MHz, 
CDCl3) δ 152.6, 139.1, 137.2, 130.3, 130.0, 129.9, 129.3, 129.1, 128.7, 126.2, 120.9, 115.9, 21.6 
ppm; HRMS (FAB, 3-NBA matrix) calcd. for C13H12O (M+), 184.0888; found, 184.0886 m/z. 
 
 D(I) (8.30 g, 90 %) as clear oil: 1H NMR (400 MHz, CDCl3) δ 7.40-7.38 (2H, m), 
7.34-7.30 (2H, m), 7.28-7.25 (2H, m), 7.03-6.99 (2H, m), 2.45 ppm (3H, s); 13C NMR (100 MHz, 
CDCl3) δ 152.7, 137.7, 134.3, 130.4, 130.1, 129.1, 129.1, 128.3, 121.0, 116.0, 21.3 ppm; HRMS 
(FAB, 3-NBA matrix) calcd. for C13H12O (M+), 184.0888; found, 184.0893 m/z. 
 
 E(I) (9.10 g, 98 %) as clear oil: 1H NMR (400 MHz, CDCl3) δ 7.42-7.26 (4H, m), 
7.21-7.18 (2H, m), 7.09-7.07 (1H, dd, J = 4.1 Hz, 2.4 Hz), 6.86-6.81 (1H, ddd, J = 13.6, 2.5, 0.9 
Hz), 2.42 ppm (3H, s); 13C NMR (100 MHz, CDCl3) δ 155.8, 143.2, 140.8, 138.5, 130.1, 128.8, 
128.4, 128.0, 127.0, 124.3, 120.0, 114.3, 21.6 ppm; HRMS (FAB, 3-NBA matrix) calcd. for 
C13H12O (M+), 184.0888; found, 184.0882 m/z. 
 
 G(I) (9.00 g, 97 %) as clear oil: 1H NMR (400 MHz, CDCl3) δ 7.50 (2H, d, J = 8.6 Hz), 
                                                  
1 M. Cowart, R. Faghih, M. P. Curtis, G. A. Gfesser, Y. L. Bennani, L. A. Black, L. Pan, K. C. Marsh, J. P. Sullivan, 
T. A. Esbenshade, G. B. Fox, A. A. Hancock , J. Med. Chem. 2005, 48, 38-55. 
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7.39-7.28 (3H, m), 6.92 (2H, d, J = 8.7 Hz), 2.44 ppm (3H, s); 13C NMR (100 MHz, CDCl3) δ 
154.9, 140.8, 138.6, 134.4, 128.9, 128.7, 127.8, 127.7, 124.0, 115.9, 21.7 ppm; HRMS (FAB, 
3-NBA matrix) calcd. for C13H12O (M+), 184.0888; found, 184.0886 m/z. 
 
 H(I) (8.10 g, 88 %) as clear oil: 1H NMR (400 MHz, CDCl3) δ 7.48 (4H, t, J = 8.7 Hz), 
7.25 (2H, d, J = 7.9 Hz), 6.92 (2H, d, J = 8.7 Hz), 2.41 ppm (3H, s); 13C NMR (100 MHz, 
CDCl3) δ 154.8, 137.9, 136.5, 134.1, 129.5, 128.2, 126.6, 115.6, 21.1 ppm; HRMS (FAB, 3-NBA 
matrix) calcd. for C13H12O (M+), 184.0888; found, 184.0883 m/z. 
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b. Preparation of C(II).  To a cooled (0 oC) solution of C(I) (8.50 g, 46.1 mmol) and imidazole 
(9.35 g, 137 mmol) in DMF (130 mL ) was added TBDPSCl (14.2 mL, 55.0 mmol) dropwise 
over 15 minutes. Upon complete addition, the cooling bath was removed and solution was stirred 
at ambient temperature overnight.  Afterwards, water (ca 50 mL) was added the mixture 
extracted ether (3 x 100 mL).  The combined organic layers were dried (anhydrous magnesium 
sulfate), filtered and concentrated via rotovap.  The residue was chromatographed on flash 
silica (ca 150 g, 5.0 % ethyl acetate in hexanes) to give C(II) (18.3 g, 98 %) as clear oil: 1H 
NMR (400 MHz, CDCl3) δ 7.68-7.63 (4H, dd, J = 9.6, 1.9 Hz), 7.46-7.28 (10H, m), 7.18 (1H, d, 
J = 7.2 Hz), 6.96-6.88 (2H, m), 6.54-6.50 (1H, dd, J = 7.7, 1.5 Hz), 2.43 (3H, s), 0.88 ppm (9H, 
s); 13C NMR (100 MHz, CDCl3) δ 152.5, 139.1, 137.2, 135.6, 134.9, 133.2, 133.0, 130.9, 129.9, 
129.3, 128.0, 127.8, 127.6, 126.9, 121.3, 119.8, 26.3, 21.6, 19.5 ppm; HRMS (FAB, 3-NBA 
matrix) calcd. for C29H30OSiLi [(M+Li)+], 429.2226; found, 429.2217 m/z. 
 
 D(II) (17.5 g, 93 %) as a clear oil: 1H NMR (400 MHz, CDCl3) δ 7.69-7.66 (4H, dd, J = 
9.6 Hz, 1.8 Hz), 7.45-7.36 (11H, m), 6.96-6.86 (2H, m), 6.57-6.51 (1H, dd, J = 7.9, 1.3 Hz), 2.45 
(3H, s), 0.89 ppm (9H, s); 13C NMR (100 MHz, CDCl3) δ 152.6, 136.4, 135.6, 135.3, 134.9, 
133.0, 130.9, 129.9, 129.8, 129.7, 128.7, 127.8, 121.3, 119.9, 26.7, 21.4, 19.5 ppm; HRMS (FAB, 
3-NBA matrix) calcd. for C29H30OSiLi [(M+Li)+], 429.2226; found, 429.2215 m/z. 
 
 E(II) 1H NMR (400 MHz, CDCl3) δ 7.81-7.76 (4H, dd, J = 7.9 Hz, 1.3 Hz), 7.49-7.38 
(6H, m), 7.25 (1H, d, J = 7.8 Hz), 7.20-7.10 (5H, m), 6.98 (1H, t, J = 2.0 Hz), 6.80-6.75 (1H, ddd, 
J = 8.0, 2.4, 1.0 Hz), 2.38 (3H, s), 1.16 ppm (9H, s); 13C NMR (100 MHz, CDCl3) δ 156.0, 142.5, 
140.9, 138.2, 135.7, 133.1, 130.0, 129.5, 129.4, 128.6, 128.0, 127.9, 124.2, 120.0, 118.7, 118.6, 
26.7, 21.5, 19.6 ppm; HRMS (FAB, 3-NBA matrix) calcd. for C29H30OSiLi [(M+Li)+], 429.2226; 
found, 429.2216 m/z. 
 
 G(II) (17.9 g, 95 %) as clear oil: 1H NMR (400 MHz, CDCl3) δ 7.81-7.75 (4H, dd, J = 
7.9 Hz, 1.4 Hz), 7.48-7.30 (11H, m), 7.10 (1H, d, J = 7.0 Hz), 6.87-6.82 (2H, dd, J = 9.6, 2.4 Hz), 
2.40 (3H, s), 1.15 ppm (9H, s); 13C NMR (100 MHz, CDCl3) δ 155.2, 140.8, 138.2, 135.6, 134.1, 
133.0, 129.9, 128.6, 127.9, 127.8, 127.5, 127.4, 123.8, 119.9, 26.6, 21.6, 19.5 ppm; HRMS (FAB, 
3-NBA matrix) calcd. for C29H30OSi [(M+)], 429.2066; found, 429. 2070 m/z. 
S3 
 
 H(II) (16.3 g, 87 %) as white solid: mp 105-106 °C; 1H NMR (400 MHz, CDCl3) δ 
7.79-7.73 (5H, m), 7.48-7.39 (9H, m), 7.20 (2H, d, J = 7.9 Hz), 6.87-6.81 (2H, dd, J = 6.5, 2.0 
Hz), 2.37 (3H, s), 1.15 ppm (9H, s); 13C NMR (100 MHz, CDCl3) δ 155.0, 138.0, 135.6, 134.9, 
130.0, 129.7, 129.4, 127.9, 127.8, 127.7, 126.6, 119.9, 26.6, 21.1, 19.6 ppm; HRMS (FAB, 
3-NBA matrix) calcd. for C29H30OSi [(M+)], 429.2066; found, 429. 2079 m/z. 
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c. Preparation of (R,R)-C(IV).  Step i: Preparation of bromide C(III).  A solution of C(II) 
(5.50 g, 13.6 mmol), NBS (2.42 g, 13.6 mmol) and AIBN (111 mg, 0.68 mmol) dry benzene (100 
mL ) was heated at reflux for 6 hours. The reaction was monitored by TLC for disappearance of 
starting material.  Afterwards, the reaction mixture was cooled to room temperature during 
which time a solid separates.  The mixture is filtered and the filtrate concentrated via rotovap.  
Hexane was added to the residue and the resulting precipitates were removed via filtration.  The 
filtrate was concentrated via rotovap to give bromide C(III), which was used without further 
purification.   
 Step ii: Preparation of substituted box derivative (R,R)-C(IV).  To a stirred, cooled 
(-78 oC) solution of 2,2’-methylenebis[(4R)-4-phenyl-4,5-dihydro-2-oxazole] (4.00 g, 13.1 
mmol) in dry THF (10 mL) was added dropwise a solution of sodium bis(trimethylsilyl) amide 
(13.1 mL of a 1.0 M solution in THF, 13.1 mmol). The resulting mixture was stirred (-78 oC, 2 h) 
then a solution of crude bromide C(III) (ca. 13.6 mmol) in a dry THF (15 mL) was added 
dropwise. The resulting reaction mixture was allowed to slowly warm to room temperature and 
stirred for a total of 12 h. The reaction was quenched by the addition of satd aq. NH4Cl and 
extracted with CH2Cl2 (2 x 120 mL). The combined organic extracts were washed with brine, 
dried (Na2SO4) and concentrated via rotovap. Flash chromatography on silica (95:5 
CH2Cl2:MeOH) affords (R,R)-C(IV) (7.78 g, 82 %) as a colorless solid: mp 89-90 oC; [α]D25 = 
+24.2 (c = 0.8, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.56-7.54 (2H, m), 7.45-7.22 (17H, m), 
7.08 (2H, dd, J = 7.9, 7.8 Hz), 6.92-6.90 (2H, m), 6.57-6.54 (2H, m), 5.28 and 5.20 (2H, 
overlapping t, J= 10.0, 10.0 Hz), 4.68 and 4.65 (2H, overlapping dd, J= 10.1, 10.1 Hz), 4.17 (1H, 
dd, J = 8.2, 8.1 Hz), 4.13-4.08 (2H, m), 3.57-3.46 (2H, m), 0.87 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ 165.8, 165.6, 152.5, 142.2, 139.5, 137.7, 135.5, 132.91, 132.88, 132.85, 130.9, 130.6, 
129.9, 128.9, 128.7, 128.6, 128.13, 128.07, 127.8, 127.63, 127.57, 126.8, 126.7, 126.5, 121.3, 
119.8, 75.5, 75.2, 69.72, 69.70, 41.5, 36.0, 26.34, 19.4 ppm; HRMS (FAB, 3-NBA matrix) calcd. 
for C48H47N2O3Si [(M+H)+], 727.3356; found, 727.3349 m/z. 
 
 (R,R)-D(IV) (8.11 g, 85 %) as a colorless solid: mp 84-85 oC; [α]D25 = +28.0 (c = 1.1, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.71-7.65 (5H, m), 7.63-7.58 (2H, m), 7.44-7.24 (14H, 
m), 7.12 (2H, dd, J = 8.1, 8.0 Hz), 6.97-6.87 (2H, m), 6.55 (1H, dd, J = 8.0, 7.9 Hz), 5.28 and 
S4 
5.22 (2H, overlapping t, J= 10.0, 10.0 Hz), 4.71 and 4.68 (2H, overlapping dd, J= 10.4, 10.3 Hz), 
4.21 (1H, dd, J = 8.1, 8.1 Hz), 4.17-4.10 (2H, m), 3.59-3.51 (2H, m), 0.88 ppm (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ 165.8, 165.6, 152.6, 142.2, 142.2, 137.7, 136.7, 135.6, 132.91, 
132.89, 132.7, 131.0, 130.2, 130.0, 128.9, 128.8, 128.1, 127.9, 127.7, 127.6, 126.8, 126.6, 121.4, 
120.0, 75.5, 75.3, 69.80, 69.78, 41.6, 35.9, 26.5, 19.5 ppm; HRMS (FAB, 3-NBA matrix) calcd. 
for C48H47N2O3Si [(M+H)+], 727.3356; found, 727.3373 m/z. 
 
 (R,R)-E(IV) (8.32 g, 88 %) as a colorless solid: mp 82-83 oC; [α]D25 = +21.0 (c = 1, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.81-7.75 (4H, m), 7.49-7.22 (19H, m), 7.17-7.08 (2H, 
m), 7.01-6.96 (2H, m), 6.76 (1H, dd, J = 7.9, 7.8 Hz), 5.25-5.19 (2H, m), 4.67 and 4.65 (2H, 
overlapping dd, J= 10.1, 10.3 Hz), 4.17 (1H, dd, J = 8.2, 8.2 Hz), 4.08-4.01 (2H, m), 3.50-3.38 
(2H, m), 1.16 ppm (s, 9H); 13C NMR (100 MHz, CDCl3) δ 165.49, 165.46, 156.0, 142.1, 142.0, 
141.1, 138.4, 135.69, 135.66, 133.0, 130.1, 129.6, 129.0, 128.9, 128.8, 128.7, 128.1, 128.0, 127.7, 
127.6, 126.74, 126.72, 126.5, 125.5, 120.0, 118.7, 75.5, 75.2, 69.74, 69.69, 41.5, 36.0, 26.7, 19.6 
ppm; HRMS (FAB, 3-NBA matrix) calcd. for C48H47N2O3Si (M+H) +, 727.3356; found, 
727.3342 m/z [(M+H)+]. 
 
 (S,S)-E(IV) (8.18 g, 86 %) as a colorless solid: mp 82-83 oC; [α]D25 = -20.1 (c = 2.2, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.81-7.75 (4H, m), 7.48-7.22 (19H, m), 7.15-7.06 (2H, 
m), 7.01-6.95 (2H, m), 6.76 (1H, dd, J = 7.9 Hz, 7.9 Hz), 5.26-5.20 (2H, m), 4.67 and 4.64 (2H, 
overlapping dd, J= 10.2, 10.2 Hz), 4.18 (1H, dd, J = 8.3, 8.3 Hz), 4.08-4.00 (2H, m), 3.51-3.38 
(2H, m), 1.15 ppm (s, 9H); 13C NMR (100 MHz, CDCl3) δ 165.51, 165.47, 156.0, 142.2, 142.1, 
141.2, 138.5, 135.7, 135.7, 133.0, 130.1, 129.6, 129.5, 129.0, 128.9, 128.8, 128.7, 128.2, 128.0, 
127.7, 127.6, 126.8, 126.5, 125.5, 120.0, 118.7, 75.5, 75.2, 69.8, 69.7, 41.6, 36.0, 26.7, 19.6 
ppm; HRMS (FAB, 3-NBA matrix) calcd. for C48H47N2O3Si (M+H) +, 727.3356; found, 
727.3349 m/z [(M+H)+]. 
 
 (R,R)-G(IV) (8.51 g, 89 %) as a colorless solid: mp 91-92 oC; [α]D25 = +20.2 (c = 1.8, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.80-7.73 (5H, m), 7.49-7.18 (19H, m), 7.17-7.08 (2H, 
m), 7.05-6.96 (2H, m), 6.69 (1H, d, J = 8.4 Hz), 5.26-5.15 (2H, m), 4.69 and 4.61 (2H, 
overlapping dd, J= 10.0, 10.3 Hz), 4.15 (1H, dd, J = 7.9, 7.9 Hz), 4.10-4.03 (2H, m), 3.53-3.40 
(2H, m), 1.16 ppm (s, 9H); 13C NMR (100 MHz, CDCl3) δ 165.5 (2C), 155.3, 142.13, 142.05, 
141.1, 138.5, 135.6, 133.9, 133.0, 130.1, 129.0, 128.9, 128.8, 128.7, 128.0, 127.9, 127.7, 127.65, 
127.63, 127.5, 126.74, 126.72, 120.1, 75.5, 75.2, 69.73, 69.68, 41.5, 36.1, 26.7, 19.6 ppm; 
HRMS (FAB, 3-NBA matrix) calcd. for C48H47N2O3Si [(M+H)+], 727.3356; found, 727.3361 
m/z. 
 
 (S,S)-H(IV) (8.54 g, 79 %) as a colorless solid: mp 96-98 oC; [α]D25 = -30.8 (c = 2.0, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.80-7.78 (4H, m), 7.49-7.17 (19H, m), 6.96-6.94 (2H, 
m), 6.89-6.87 (2H, m), 5.32 and 5.19 (2H, overlapping t, J= 10.0, 10.1 Hz), 4.69 and 4.66 (2H, 
overlapping dd, J= 8.5, 8.5 Hz), 4.19 (1H, dd, J = 8.2, 8.2 Hz), 4.12-4.05 (2H, m), 3.52-3.39 (2H, 
m), 1.15 ppm (s, 9H); 13C NMR (100 MHz, CDCl3) δ 165.5, 165.4, 155.3, 142.2, 142.0, 139.4, 
136.4, 135.7, 133.7, 133.0, 130.1, 129.6, 128.8, 128.7, 128.0, 127.9, 127.7, 127.6, 126.9, 126.8, 
126.7, 120.2, 75.5, 75.2, 69.73, 69.70, 41.5, 35.6, 26.8, 19.6 ppm; HRMS (FAB, 3-NBA matrix) 
calcd. for C48H47N2O3Si [(M+H)+], 727.3356; found, 727.3351 m/z. 
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d. Preparation of (R,R)-C(V).  To a solution of (R,R)-C(IV) (8.00 g, 11.0 mmol) dry THF (100 
mL ) was added dropwise tetrabutylammonium fluoride (TBAF, 11.0 mL of a 1.0 M solution in 
THF, 11.0 mmol).  After 10 h, the mixture was partitioned between CH2Cl2 (80 mL)-water (80 
mL). The organic layer was dried (Na2SO4) and concentrated. Chromatography on silica gel 
(90:10 CH2Cl2:MeOH) gave (R,R)-C(V) (4.90 g, 91%) as a colorless solid: mp 124-126 0C; 
[α]D25 = 18.8 (c = 0.6, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.44-7.20 (14H, m), 7.02-6.96 
(4H, m), 5.24 and 5.20 (2H, overlapping t, J = 10.8, 10.8 Hz), 4.71 and 4.66 (2H, overlapping dd, 
J = 8.5, 8.5 Hz), 4.19 (1H, dd, J = 8.2, 8.1 Hz), 4.14-4.07 (2H, m), 3.55-3.43 ppm (2H, m); 13C 
NMR (100 MHz, CDCl3) δ 165.8, 165.7, 153.3, 141.9, 141.8, 138.3, 138.2, 130.4, 130.0, 129.1, 
128.81, 128.77, 128.71, 128.2, 128.1, 127.8, 127.7, 127.6, 126.72, 126.69, 120.3, 116.3, 75.5, 
75.3, 69.4 (2C), 41.3, 35.8 ppm; HRMS (FAB, 3-NBA matrix) calcd. for C32H29N2O3 [(M+H)+], 
489.2178; found, 489.2180 m/z. 
 
 (R,R)-D(V) (5.17 g, 96%) as a colorless solid: mp 120-122 0C; [α]D25 = 18.7 (c = 0.7, 
CH2Cl2); 1H NMR (400 MHz,CDCl3) δ 7.50-7.41 (4H, dd, J = 19.6, 8.1 Hz), 7.36-7.19 (10H, m), 
7.04 (2H, dd, J = 7.8, 7.0 Hz), 7.01 (1H, dd, J = 8.6, 8.4 Hz), 6.93 (1H, d, J = 8.0 Hz), 5.27-5.21 
(2H, m), 4.74 and 4.68 (2H, overlapping dd, J = 8.5, 8.3 Hz), 4.22 (2H, dd, J = 8.2, 8.1 Hz), 4.13 
(1H, dd, J = 8.5, 8.5 Hz), 3.54-3.43 ppm (2H, m); 13C NMR (100 MHz, CDCl3) δ 166.0, 165.9, 
153.7, 141.8, 141.7, 136.9, 136.5, 130.5, 129.5, 129.3, 128.82, 128.78, 128.6, 128.2, 127.8, 127.7, 
126.8, 126.7, 120.2, 116.3, 75.6, 75.4, 69.41, 69.38, 41.3, 35.6 ppm; HRMS (FAB, 3-NBA 
matrix) calcd. for C32H29N2O3 [(M+H)+], 489.2178; found, 489.2170 m/z. 
 
 (R,R)-E(V) (5.00 g, 93%) as a colorless solid: mp 113-114 0C; [α]D25 = 22.5 (c = 1.1, 
CH2Cl2); 1H NMR (400 MHz,CDCl3) δ 7.54 (1H, s), 7.44 (1H, d, J = 7.6 Hz), 7.36-7.11 (12H, 
m), 7.05-7.03 (2H, m), 6.97-6.94 (2H, m), 6.66 (1H, dd, J = 8.2, 8.0 Hz), 5.26-5.20 (2H, m), 
4.72-4.66 (2H, m), 4.23-4.17 (2H, m), 4.09 (1H, dd, J = 8.0, 8.0 Hz), 3.56-3.43 ppm (2H, m); 13C 
NMR (100 MHz, CDCl3) δ 166.1 (2C), 157.4, 142.3, 141.7, 141.6, 141.5, 137.9, 129.6, 129.0, 
128.9, 128.8, 128.0, 127.8, 127.7, 126.72, 126.68, 126.4, 125.8, 118.5, 114.64, 114.58, 75.7, 75.4, 
69.3, 69.2, 41.4, 35.8 ppm; HRMS (FAB, 3-NBA matrix) calcd. for C32H29N2O3 [(M+H)+], 
489.2178; found, 489.2165 m/z. 
 
 (S,S)-E(V) (5.00 g, 93%) as a colorless solid: mp 113-114 0C; [α]D25 = -19.3 (c = 1.3, 
CH2Cl2); 1H NMR (400 MHz,CDCl3) δ 7.53 (1H, s), 7.45 (1H, d, J = 7.6 Hz), 7.36-7.10 (12H, 
m), 7.05-7.02 (2H, m), 6.97-6.94 (2H, m), 6.67 (1H, dd, J = 8.7, 8.1 Hz), 5.25-5.20 (2H, m), 
4.72-4.67 (2H, m), 4.23-4.16 (2H, m), 4.09 (1H, dd, J = 8.3, 8.3 Hz), 3.56-3.43 ppm (2H, m); 13C 
NMR (100 MHz, CDCl3) δ 166.09, 166.07, 157.4, 142.3, 141.7, 141.6, 141.5, 137.9, 129.6, 
129.0, 128.9, 128.8, 128.0, 127.8, 127.7, 126.73, 126.69, 126.4, 125.8, 118.5, 114.64, 114.59, 
S6 
75.7, 75.4, 69.32, 69.25, 41.4, 35.8 ppm;. HRMS (FAB, 3-NBA matrix) calcd. for C32H29N2O3 
[(M+H)+], 489.2178; found, 489.2171 m/z. 
 
 (R,R)-G(V) (4.88 g, 91%) as a colorless solid: mp 110-111 0C; [α]D25 = 29.8 (c = 0.7, 
CH2Cl2); 1H NMR (400 MHz,CDCl3) δ 7.45-7.43 (2H, m), 7.37-7.20 (13H, m), 6.99-6.96 (2H, 
m), 6.65 (2H, dd, J = 8.4, 8.4 Hz), 5.27-5.22 (2H, m), 4.75-4.69 (2H, m), 4.24 and 4.20 (2H, 
overlapping dd, J = 8.2, 7.8 Hz), 4.13 (1H, dd, J = 8.5, 8.5 Hz), 3.54-3.47 ppm (2H, m); 13C 
NMR (100 MHz, CDCl3) δ 166.2, 166.1, 156.7, 141.7, 141.5, 141.4, 137.9, 132.1, 129.0, 128.9, 
128.8, 128.1, 127.9, 127.8, 127.3, 127.2, 126.8, 126.7, 125.3, 115.9, 75.6, 75.5, 69.3, 69.2, 41.4, 
35.9 ppm; HRMS (FAB, 3-NBA matrix) calcd. for C32H29N2O3 [(M+H)+], 489.2178; found, 
489.2176 m/z. 
 
 (S,S)-H(V) (5.10 g, 95%) as a colorless solid: mp 129-130 0C; [α]D25 = -33.8 (c = 2.0, 
CH2Cl2); 1H NMR (400 MHz,CDCl3) δ 7.38-7.30 (9H, m), 7.26-7.19 (5H, m), 7.01 (2H, dd, J = 
8.8, 7.4 Hz), 6.46 (2H, d, J = 8.6 Hz), 5.30 and 5.24 (2H, overlapping t, J= 10.0, 10.1 Hz), 4.80 
and 4.74 (2H, overlapping dd, J= 8.5, 8.5 Hz), 4.29 (1H, dd, J = 8.2, 8.2 Hz), 4.25 and 4.19 (2H, 
overlapping dd, J = 8.5, 8.5 Hz), 3.56-3.41 ppm (2H, m); 13C NMR (100 MHz, CDCl3) δ 166.0, 
165.9, 156.6, 141.6, 141.2, 139.6, 135.4, 131.6, 129.4, 129.1, 128.8, 128.7, 127.8, 127.7, 126.9, 
126.7, 126.5, 116.1, 75.7, 75.5, 69.3, 69.2, 41.7, 35.3 ppm; HRMS (FAB, 3-NBA matrix) calcd. 
for C32H29N2O3 [(M+H)+], 489.2178; found, 489.2167 m/z. 
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e. Preparation of (R,R)-1C (adapted from the procedure of Kranich et al.) 2 .  
(R,R)-TADDOL)PCl ((R)-C(VI)) was prepared according to the published procedure.3  To a 
solution of (R,R)-C(V) (300 mg, 0.61 mmol), Et3N (1.70 mL, 12.2 mmol), and DMAP (3.7 mg, 
0.03 mmol) in dry THF (15 mL) was added dropwise a solution of (R,R)-TADDOL)PCl 
((R)-C(VI)) (389 mg, 0.73 mmol) in dry THF (7 mL).  The resulting milky suspension was 
stirred at room temperature (ca. 12 h) and then filtered under nitrogen through a short pad of 
celite.  The celite was washed with degassed THF and the combined filtrates concentrated to 
dryness on a vacuum line using care to insure the product is keep oxygen-free.  Rapid 
chromatography of the residue on a short column of silica gel using degassed solvent (95:5 
CH2Cl2:MeOH) afforded (R,R)-1C (482 mg, 80%) as a colorless solid: mp 131-132 0C; [α]D25 = 
-105.5 (c = 0.3, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.42-7.17 (36H, m), 7.04-6.98 (2H, m), 
5.24-5.13 (2H, m), 5.07 (2H, s), 4.63-4.57 (2H, m), 4.12 (1H, dd, J = 8.1, 8.1 Hz), 4.04-4.00 (2H, 
                                                  
2 R. Kranich, K. Eis, O. Geis, S. Mühle, J. W. Bats, H.-G. Schmalz. Chem.Eur. J. 2000, 6, 2874-2894. 
3 J. Sakaki, W. B. Schweizer, D. Seebach, Helv. Chim. Acta 1993, 76, 2654-2665. 
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m), 3.36 (2H, d, J = 8.1 Hz), 1.00 (3H, s), 0.36 ppm (3H, s); 13C NMR (100 MHz, CDCl3) δ 
165.53, 165.45, 148.8, 145.6, 145.2, 142.15, 142.10, 141.29, 141.26, 140.7, 138.5, 137.8, 134.4, 
130.8, 130.6, 128.7, 128.65, 128.62, 128.5, 128.2, 128.1, 128.06, 127.8, 127.6, 127.51, 127.48, 
127.45, 127.40, 127.32, 127.30, 127.2, 127.1, 127.0, 126.9, 126.7, 124.2, 122.3, 122.2, 113.1, 
85.6 (d, JCP = 8.0 Hz), 83.2, 82.2 (d, JCP = 15.2 Hz), 81.0 (d, JCP = 4.0 Hz), 75.3, 75.1, 69.6, 69.5, 
41.2, 35.8, 27.2, 25.7 ppm; 31P NMR (162 MHz, CDCl3) δ 134.4 ppm; HRMS (FAB, 3-NBA 
matrix) calcd. for C63H56N2O7P [(M+H)+], 983.3825; found, 983.3830 m/z. 
 
 (R,R)-1D (461 mg, 77%) as a colorless solid: mp 138-139 0C; [α]D25 = -158.0 (c = 0.2, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.44-7.12 (36H, m), 7.04-7.02 (2H, m), 5.23-5.18 (2H, 
m), 5.10 (2H, s), 4.66-4.60 (2H, m), 4.17 (1H, dd, J = 8.2, 8.2 Hz), 4.12-4.05 (2H, m), 3.57-3.45 
(2H, m), 0.98 (3H, s), 0.39 ppm (3H, s); 13C NMR (100 MHz, CDCl3) δ 165.5, 165.47, 149.0, 
145.5, 145.2, 142.1, 142.0, 141.39, 141.36, 140.7, 136.7, 136.6, 134.03, 134.01, 130.8, 130.1, 
128.7, 128.69, 128.66, 128.2, 128.1, 127.8, 127.76, 127.6, 127.53, 127.50, 127.29, 127.26, 
127.17, 127.07 126.99, 126.72, 126.70, 124.2, 122.1, 122.0, 113.2, 86.0 (d, JCP = 8.9 Hz), 83.3, 
82.1 (d, JCP = 14.5 Hz), 80.9 (d, JCP = 4.5 Hz), 75.4, 75.2, 69.7, 69.6, 41.4, 35.6, 27.1, 25.8 ppm; 
31P NMR (162 MHz, CDCl3) δ 134.9 ppm; HRMS (FAB, 3-NBA matrix) calcd. for C63H56N2O7P 
[(M+H)+], 983.3825; found, 983.3840 m/z. 
 
 (R,R)-1E (527 mg, 88%) as a colorless solid: mp 125-126 0C; [α]D25 = -75.2 (c = 0.6, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.65-7.62 (2H, m), 7.58-7.51 (5H, m), 7.48 (3H, s), 
7.38-7.15 (24H, m), 7.05-7.03 (2H, m), 6.73 (1H, s), 6.56 (1H, dd, J = 7.8, 1.2 Hz), 5.68 (1H, d, 
J = 8.3 Hz), 5.27 and 5.23 (2H, overlapping dd, J = 8.2, 8.2 Hz), 5.14 (1H, d, J = 8.3 Hz), 4.71 
and 4.66 (2H, overlapping dd, J = 9.9, 9.6 Hz), 4.20 (1H, dd, J = 8.2, 5.6 Hz), 4.17-4.08 (2H, m), 
3.59-3.48 (2H, m), 0.87 (3H, s), 0.69 ppm (3H, s); 13C NMR (100 MHz, CDCl3) δ 165.44, 165.41, 
152.5 (d, JCP = 6.6 Hz), 146.0, 142.1, 142.0, 141.96, 141.4, 141.3, 140.7, 138.5, 129.3, 129.2, 
128.9, 128.7, 128.65, 128.2, 128.1, 127.9, 127.7, 127.6, 127.5, 127.4, 127.3, 127.2, 127.16, 
127.14, 126.9, 126.8, 126.7. 126.6, 126.4, 125.6, 121.9, 118.6, 118.5, 118.5, 118.4, 113.0, 86.6 (d, 
JCP = 11.0 Hz), 85.2 (d, JCP = 7.1 Hz), 82.3 (d, JCP = 10.2 Hz), 80.2 (d, JCP = 5.1 Hz), 75.4, 75.2, 
69.7, 69.6, 41.5, 36.0 26.8, 26.4 ppm; 31P NMR (162 MHz, CDCl3) δ 126.0 ppm; HRMS (FAB, 
3-NBA matrix) calcd. for C63H56N2O7P [(M+H)+], 983.3825; found, 983.3835 m/z. 
 
 (S,S)-1E (540 mg, 90%) as a colorless solid: mp 123-124 0C; [α]D25 = -74.0 (c = 0.3, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.64-7.62 (2H, m), 7.57-7.51 (7H, m), 7.47 (1H, s), 
7.41-7.16 (24H, m), 7.05-7.03 (2H, m), 6.72 (1H, s), 6.56 (1H, dd, J = 7.8, 1.2 Hz), 5.67 (1H, d, 
J = 8.3 Hz), 5.27 and 5.23 (2H, overlapping dd, J = 8.2, 8.2 Hz), 5.14 (1H, d, J = 8.3 Hz), 4.71 
and 4.66 (2H, overlapping dd, J = 9.9, 9.6 Hz), 4.21 (1H, dd, J = 8.2, 5.6 Hz), 4.17-4.08 (2H, m), 
3.59-3.48 (2H, m), 0.86 (3H, s), 0.65 ppm (3H, s); 13C NMR (100 MHz, CDCl3) δ 165.44, 165.39, 
152.5 (d, JCP = 6.6 Hz), 146.0, 142.1, 142.04, 141.96, 141.4, 141.3, 140.7, 138.5, 129.5, 129.3, 
129.1, 128.9, 128.7, 128.69, 128.65, 128.2, 128.1, 127.9, 127.7, 127.6, 127.5, 127.4, 127.3, 127.2, 
127.1, 126.7. 126.6, 126.4, 125.6, 122.1, 121.9, 118.6, 118.5, 118.5, 118.4, 113.0, 86.6 (d, JCP = 
11.5 Hz), 85.2 (d, JCP = 7.9 Hz), 82.3 (d, JCP = 10.1 Hz), 80.2 (d, JCP = 4.5 Hz), 75.4, 75.2, 69.7, 
69.6, 41.5, 36.0 26.7, 26.4 ppm; 31P NMR (162 MHz, CDCl3) δ 126.0 ppm; HRMS (FAB, 
3-NBA matrix) calcd. for C63H56N2O7P [(M+H)+], 983.3825; found, 983.3833 m/z. 
 
 (R,R)-1G (500 mg, 83%) as a colorless solid: mp 134-135 0C; [α]D25 = -98.5 (c = 0.4, 
S8 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.66-7.63 (2H, m), 7.59-7.52 (7H, m), 7.46-7.22 (24H, 
m), 7.04-7.02 (2H, m), 6.59 (2H, d, J = 7.9 Hz), 5.65 (1H, d, J = 8.2 Hz), 5.28 (2H, m), 5.15 (1H, 
d, J = 8.3 Hz), 4.73-4.68 (2H, m), 4.19 (1H, dd, J = 8.2, 8.2 Hz), 4.16-4.09 (2H, m), 3.59-3.46 
(2H, m), 0.85 (3H, s), 0.70 ppm (3H, s); 13C NMR (100 MHz, CDCl3) δ 165.5 (2C), 151.7 (d, JCP 
= 5.6 Hz), 145.97, 145.93, 142.0, 141.97, 141.3, 140.9, 138.5, 136.0, 129.2, 129.0, 128.95, 128.8, 
128.7, 128.67, 128.2, 128.1, 128.0, 127.8, 127.7, 127.6, 127.5, 127.4, 127.3, 127.2, 127.19, 
127.17, 126.7, 126.67, 126.64, 126.4, 125.3, 120.1, 120.06, 113.1, 86.8 (d, JCP = 11.7 Hz), 85.2 
(d, JCP = 6.9 Hz), 82.3 (d, JCP = 9.9 Hz), 80.2 (d, JCP = 5.2 Hz), 75.5, 75.2, 69.7, 69.6, 41.4, 36.0, 
26.7, 26.4 ppm; 31P NMR (162 MHz, CDCl3) δ 136.4 ppm; HRMS (FAB, 3-NBA matrix) calcd. 
for C63H56N2O7P [(M+H)+], 983.3825; found, 983.3789 m/z. 
 
 (S,S)-1H (572 mg, 95%) as a colorless solid: mp 139-141 0C; [α]D25 = -87.5 (c = 0.3, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.67-7.65 (2H, m), 7.60-7.51 (8H, m), 7.47-7.21 (24H, 
m), 6.99-6.97 (2H, m), 6.65 (2H, d, J = 8.1 Hz), 5.66 (1H, d, J = 8.4 Hz), 5.30-5.23 (2H, m), 5.16 
(1H, d, J = 8.3 Hz), 4.74 and 4.70 (2H, overlapping dd, J = 8.6, 8.5 Hz), 4.22 (1H, dd, J = 8.2, 
8.2 Hz), 4.16-4.09 (2H, m), 3.57-3.44 (2H, m), 0.84 (3H, s), 0.71 ppm (3H, s); 13C NMR (100 
MHz, CDCl3) δ 165.4, 165.3, 151.6 (d, JCP = 5.4 Hz), 146.0, 142.1, 141.9, 141.3, 139.1, 136.7, 
135.9, 129.6, 129.2, 128.9, 128.74, 128.71, 128.6, 128.2, 128.0, 127.8, 127.78 127.63, 127.60, 
127.5, 127.4, 127.3, 127.2, 127.17, 127.0, 126.8, 126.7, 126.66, 126.4, 120.3, 120.2, 113.1, 86.8 
(d, JCP = 10.9 Hz), 85.1 (d, JCP = 7.4 Hz), 82.3 (d, JCP = 10.6 Hz), 80.2 (d, JCP = 5.2 Hz), 75.5, 
75.2, 69.7, 69.6, 41.4, 35.5, 26.7, 26.5 ppm; 31P NMR (162 MHz, CDCl3) δ 126.5 ppm; HRMS 
(FAB, 3-NBA matrix) calcd. for C63H56N2O7P [(M+H)+], 983.3825; found, 983.3813 m/z. 
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f. Preparation of [(R,R)-1C]2Zn.  To a solution of (R,R)-1C (400 mg, 0.41 mmol) in dry 
degassed dichloromethane (5.0 mL) was added dropwise a solution of Zn(OAc)2 (37.6 mg, 0.21 
mmol) in dry degassed methanol (5.0 mL).  The resulting solution was stirred at room 
temperature for ca. 5 minutes and then vacuum was applied to reduce a volume by approximately 
half.  Dry degassed methanol (30.0 mL) was added to the resulting solution resulting in the 
formation of a milky suspension.  This suspension was filtered and residue was washed with 
dry degassed methanol (3 x 7.0 mL).  Residue was dried under vacuum (< 1 torr) to afford 
[(R,R)-1C]2Zn (398 mg, 96 %) as a white solid: mp 161-162 0C; [α]D25 = -175.9 (c = 0.3, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.43-7.37 (14H, m), 7.30-7.18 (41H, m), 7.10-7.02, 
(14H, m), 6.83-6.79 (7H, m), 5.09-5.04 (4H, m), 4.51-4.42 (4H, m), 4.14-4.06 (4H, m), 3.78-3.53 
(9H, m), 1.00 (6H, s), 0.36 ppm (6H, s); 13C NMR (100 MHz, CDCl3) δ 171.4, 171.3, 149.0, 
145.7, 145.3, 144.6, 141.5, 141.46, 140.7, 137.6, 135.3, 130.9, 130.1, 129.6, 129.2, 128.8, 128.7, 
128.6, 128.4, 128.2, 128.1, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 127.36, 127.31, 127.25, 
S9 
127.0, 126.99, 126.90, 126.7, 126.6, 124.2, 122.3, 122.2, 113.1, 85.8 (d, JCP = 7.9 Hz), 83.1, 82.3 
(d, JCP = 14.8 Hz), 80.9 (d, JCP = 3.8 Hz), 73.3, 68.0, 66.8, 66.4, 31.4, 27.2, 25.8, 25.7 ppm; 31P 
NMR (162 MHz, CDCl3) δ 134.3 ppm; HRMS (FAB) calcd for C126H111N4O14P2Zn [(M+H)+], 
2029.6863; found: 2029.6843 m/z. 
 
 [(R,R)-1D]2Zn (366 mg, 88 %) as a white solid: mp 158-159 0C; [α]D25 = -184.7 (c = 0.3, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.45-7.04 (69H, m), 6.86-6.83 (7H, m), 5.09-5.08 (4H, 
m), 4.56-4.52 (4H, m), 4.21-4.17 (4H, m), 3.77-3.64 (10H, m), 0.94 (6H, s), 0.35 ppm (6H, s); 
13C NMR (100 MHz, CDCl3) δ 171.4, 171.3, 149.0, 145.7, 145.3, 143.5, 141.5, 141.5, 141.4, 
140.8, 135.07, 135.05, 134.9, 130.9, 129.4, 129.2, 128.87, 128.85, 128.79, 128.5, 128.3, 128.0, 
127.8, 127.7, 127.59, 127.55, 127.50, 127.4, 127.3, 127.28, 127.1, 127.0, 126.7, 124.3, 122.4, 
122.3, 113.2, 85.9 (d, JCP = 8.9 Hz), 83.1, 82.3 (d, JCP = 14.7 Hz), 80.8 (d, JCP = 3.9 Hz), 73.3, 
68.0, 66.9, 66.4, 31.2, 27.2, 25.8, 25.7 ppm; 31P NMR (162 MHz, CDCl3) δ 134.6 ppm; HRMS 
(FAB) calcd for C126H111N4O14P2Zn [(M+H)+], 2029.6863; found: 2029.6839 m/z. 
 
 [(R,R)-1E]2Zn (405 mg, 97 %) as a white solid: mp 164-165 0C; [α]D25 = -204.3 (c = 0.2, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.66-7.64 (5H, m), 7.76-7.53 (14H, m), 7.44-7.19 (42H, 
m), 7.12-7.06 (8H, m), 6.85-6.83 (7H, m), 5.70 (2H, d, J = 8.2 Hz), 5.17 (2H, d, J = 8.2 Hz), 
4.61-4.56 (4H, m), 4.36-4.32 (4H, m), 3.85-3.73 (10H, m), 0.87 (6H, s), 0.71 ppm (6H, s); 13C 
NMR (100 MHz, CDCl3) δ 171.4, 171.3, 152.5 (d, JCP = 6.5 Hz), 146.04, 146.02, 145.99, 145.5, 
145.4, 143.2, 141.4, 141.3, 140.0, 132.5, 130.1, 129.2, 128.8, 128.4, 128.35, 128.33, 128.2, 
128.15, 128.0, 127.7, 127.5, 127.47, 127.42, 127.37, 127.31, 127.2, 127.18, 127.15, 126.7, 124.1, 
122.1, 118.7, 118.6, 118.3, 118.2, 113.1, 86.6 (d, JCP = 10.8 Hz), 85.2 (d, JCP = 6.9 Hz), 82.3 (d, 
JCP = 10.5 Hz), 80.3 (d, JCP = 4.5 Hz), 73.5, 68.0, 66.90, 66.87, 31.6, 26.8, 26.4, 25.7 ppm; 31P 
NMR (162 MHz, CDCl3) δ 126.3 ppm; HRMS (FAB) calcd for C126H111N4O14P2Zn [(M+H)+], 
2029.6863; found: 2029.6854 m/z. 
 
 [(S,S)-1E]2Zn (397 mg, 95 %) as a white solid: mp 163-165 0C; [α]D25 = +99.0 (c = 0.3, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.66-7.64 (5H, m), 7.76-7.53 (14H, m), 7.42-7.19 (36H, 
m), 7.10-7.05 (10H, m), 6.85-6.83 (8H, m), 5.70 (2H, d, J = 8.2 Hz), 5.17 (2H, d, J = 8.2 Hz), 
4.63-4.56 (4H, m), 4.38-4.32 (4H, m), 3.83-3.73 (10H, m), 0.87 (6H, s), 0.71 ppm (6H, s); 13C 
NMR (100 MHz, CDCl3) δ 171.3, 171.3, 152.5 (d, JCP = 6.4 Hz), 146.04, 146.01, 145.4, 144.7, 
143.4, 143.2, 143.0, 141.4, 141.3, 140.2, 140.0, 129.2, 128.8, 128.7, 128.4, 128.2, 128.0, 127.9, 
127.8, 127.7, 127.5, 127.46, 127.42, 127.3, 127.2, 127.18, 126.8, 126.7, 124.2, 124.0, 122.1, 
118.6, 118.5, 118.2, 118.1, 113.1, 86.6 (d, JCP = 10.8 Hz), 85.2 (d, JCP = 6.9 Hz), 82.3 (d, JCP = 
10.5 Hz), 80.3 (d, JCP = 4.5 Hz), 73.5, 68.0, 66.90, 66.86, 31.6, 26.8, 26.4, 25.7 ppm; 31P NMR 
(162 MHz, CDCl3) δ 126.3 ppm; HRMS (FAB) calcd for C126H111N4O14P2Zn [(M+H)+], 
2029.6863; found: 2029.6887 m/z. 
 
 [(R,R)-1G]2Zn (401 mg, 96 %) as a white solid: mp 151-153 0C; [α]D25 = -146.1 (c = 
0.2, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.61-7.54 (15H, m), 7.47-7.22 (43H, m), 7.11-7.04 
(10H, m), 6.85 (8H, d, J = 6.7 Hz) , 5.67 (2H, d, J = 8.4 Hz), 5.43 (2H, d, J = 2.8 Hz), 5.18 (2H, 
d, J = 8.2 Hz), 4.63-4.57 (4H, m), 4.41-4.35 (4H, m), 3.86-3.79 (8H, m), 0.85 (6H, s), 0.70 ppm 
(6H, s); 13C NMR (100 MHz, CDCl3) δ 171.3, 171.3, 151.4 (d, JCP = 10.5 Hz), 146.0, 145.6, 
145.4, 141.4, 140.2, 137.1, 132.5, 130.1, 129.2, 129.16, 128.8, 128.4, 128.35, 128.33, 128.2, 
128.18, 128.11, 128.0, 127.9, 127.8, 127.6, 127.4, 127.3, 127.2, 127.19, 127.0, 126.7, 123.9, 
S10 
123.8, 120.1, 120.0, 119.94, 119.89, 113.2, 86.6 (d, JCP = 11.0 Hz), 85.1 (d, JCP = 6.9 Hz), 82.2 (d, 
JCP = 10.5 Hz), 80.2 (d, JCP = 4.8 Hz), 73.5, 68.0, 66.9, 66.8, 31.5, 26.6, 26.5, 25.7 ppm; 31P 
NMR (162 MHz, CDCl3) δ 126.8 ppm; HRMS (FAB) calcd for C126H111N4O14P2Zn [(M+H)+], 
2029.6863; found: 2029.6901 m/z. 
 
 [(S,S)-1H]2Zn (388 mg, 93 %) as a white solid: mp 180-181 0C; [α]D25 = +78.2 (c = 0.3, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.62-7.54 (16H, m), 7.51-7.46 (6H, m), 7.45-7.25 (33H, 
m), 7.20-7.12 (14H, m), 6.94-6.88 (7H, m), 5.64 (2H, d, J = 8.2 Hz), 5.17 (2H, d, J = 8.2 Hz), 
4.66-4.62 (4H, m), 4.42-4.38 (4H, m), 3.87-3.70 (10H, m), 0.85 (6H, s), 0.72 ppm (6H, s); 13C 
NMR (100 MHz, CDCl3) δ 171.3, 171.3, 151.2 (d, JCP = 5.7 Hz), 146.0, 144.2, 143.8, 143.4, 
142.9, 141.4, 141.35, 137.5, 136.8, 132.5, 130.1, 129.2, 128.8, 128.5, 128.47, 128.24, 128.18 
128.0, 127.9, 127.6, 127.5, 127.4, 127.3, 127.2, 127.18, 126.8, 126.5, 120.2, 120.1, 120.04, 
119.98, 113.0, 86.7 (d, JCP = 11.2 Hz), 85.0 (d, JCP = 6.7 Hz), 82.2 (d, JCP = 10.6 Hz), 80.2 (d, JCP 
= 5.1 Hz), 73.4, 68.0, 67.0, 66.9, 31.1, 26.7, 26.5, 25.7 ppm; 31P NMR (162 MHz, CDCl3) δ 
126.8 ppm; HRMS (FAB) calcd for C126H111N4O14P2Zn [(M+H)+], 2029.6863, found: 2029.6933 
m/z. 
 
 
The heterodimeric SALs can be isolated but are usually generated via in situ and used without 
isolation. Representative characterization data for the heterodimeric (SS,RR)-SAL 2(EE) is given 
below. 
[(R,R)-1E]2Zn
[(S,S)-1E]2Zn
N
O
N
O
Ph
Ph
O
OO
P
O
Ph Ph
Ph Ph
N
O
N
O
Ph
Ph
O
O O
P
O
PhPh
PhPh
Zn
+
g
(SS,RR)-SAL EE
O O
 
 
g. Preparation of (SS,RR)-SAL EE.  Solutions of [(R,R)-1E]2Zn (200 mg, 0.10 mmol) and 
[(S,S)-1E]2Zn (200 mg, 0.10 mmol), each in dry degassed dimethoxyethane (1.00 mL) were 
mixed at room temperature.  After ca. 5 minutes, the solvents were evaporated and residue dried 
under vacuum (< 1 torr) to afford (SS,RR)-SAL EE (398 mg, 99 %) as a white solid: mp 178-179 
0C; [α]D25 = -80.5 (c = 0.1, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.66 (4H, d, J = 7.4 Hz), 
7.62-7.59 (13H, m), 7.50-7.17 (47H, m), 7.06-7.05, (8H, m), 5.07 (2H, dd, J = 9.0, 8.8 Hz), 5.19, 
(4H, d, J = 8.2 Hz), 4.12-4.08 (4H, m), 3.91-3.75 (8H, m), 3.39-3.38 (2H, m), 0.87 (6H, d, J = 
7.3 Hz), 0.74 ppm (6H, d, J = 5.2 Hz);13C NMR (100 MHz, CDCl3) δ 169.8, 152.5, 146.0, 145.8, 
144.2, 143.3, 142.1, 142.0, 141.4, 140.1, 129.4, 129.3, 129.2, 129.0, 128.8, 128.7, 128.5, 128.2, 
128.0, 127.8, 127.6, 127.5, 127.45, 127.33, 127.28, 127.2, 127.1, 127.0, 126.7, 126.69, 124.0 
122.1, 118.9, 118.82, 118.79, 118.71, 118.49, 118.42, 118.40, 118.3, 113.11, 113.07, 86.7 (d, JCP 
= 4.4 Hz), 86.5 (d, JCP = 10.4 Hz), 85.2 (d, JCP = 8.2 Hz), 85.1 (d, JCP = 6.7 Hz), 82.4 (d, JCP = 
4.4 Hz), 82.2 (d, JCP = 5.9 Hz), 80.38 (d, JCP = 5.9 Hz), 80.26 (d, JCP = 6.9 Hz), 73.0, 65.7, 65.68, 
65.14, 65.12, 31.6, 26.80, 26.76, 26.72, 26.5, 26.4 ppm; 31P NMR (162 MHz, CDCl3) δ 126.3 
ppm; HRMS (FAB) calcd for C126H111N4O14P2Zn [(M+H)+], 2029.6863; found: 2029.6951 m/z. 
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1) 1% [Rh, 2.2 L]
    PBH, DME, rt
      
2) H2O2/NaOHR R R  
 
General procedure employed for the preparative scales reactions reported in Table 3 
illustrated for the preparation of 1-(2-methoxyphenyl)ethanol 3a.  A solution of 
((S,S)-1H)2Zn (10.0 mg, 1.4 x 10-2 mmol) and ((R,R)-1C)2Zn (10.0 mg, 1.4 x 10-2 mmol) in 
DCM (10 mL) was stirred at ambient temperature (RT, ca. 10 min.) and then a solution of 
Rh(nbd)2BF4 (9.7 mg, 2.6 x 10-2 mmol) in DCM (5 mL) was added.  The resulting mixture was 
stirred at ambient temperature (0.5 h) after which the volatile solvent was removed under 
vacuum.  The residue was dissolved in DME (10 mL), stirred (0.5 h) and then a solution of 
2-methoxystyrene (2a, 174.0 mg, 1.30 mmol) in DME (2.0 mL) and powdered 4Å molecular 
sieves (ca. 0.5 g) were added.  The resulting mixture was cooled (0 oC) and a solution of 
pinacolborane (199.0 mg, 1.56 mmol) in DME (4.0 mL) added dropwise. The reaction mixture 
was gradually warmed to RT and stirred (12 h).  Afterwards, the mixture was re-cooled (0 oC), 
and quenched by the addition of MeOH (10 mL), aq. NaOH (3.0 M, 15 mL), and aq. H2O2 (1 mL 
of a 30% solution).  The ice bath was removed, the resulting mixture stirred (3 h, RT) and then 
filtered.  The filtrate was extracted with ether (3 x 15 mL) and the combined organics dried 
(anhyd. Na2SO4), filtered and concentrated.  Chromatography on silica (10% EtOAc/Hex) gives 
1-(2-methoxyphenyl)ethanol (3a, 194 mg, 98%) as a clear oil: capillary GC analysis (J&W 
Scientific 30 m x 0.25 mm ID Cyclosil β, 120 oC (1 min hold) to 130o @ 1o/min then to 165o @ 
2o/min) found peaks at 21.19 (97.2%, (R)-3a) and 23.55 (2.8%, (S)-3a); [α]D25 = +25.8 (c = 1.4, 
CHCl3) (lit.4 [α]D25 = +23.7 (91% ee (R)) (c = 1.4, CHCl3)); 1H NMR (400 MHz, CDCl3) δ 7.39 
(1H, dd, J = 7.5, 1.4 Hz), 7.31 (1H, dt, J = 8.2, 1.6 Hz), 7.00 (1H, t, J = 7.5 Hz), 6.90 (1H, d, J = 
8.2 Hz), 5.13 (1H, q, J = 13.0, 6.5 Hz), 3.88 (3H, s) 1.53 ppm (3H, d, J = 6.5 Hz); 13C NMR (100 
MHz, CDCl3) 156.5, 133.6, 128.2, 126.1, 120.8, 110.4, 66.4, 55.3, 23.0 ppm; [α]D25 = +25.8o (c 
= 1.4, CHCl3). 
 
 (R)-1-(2-methylphenyl)ethanol (3b).  The title compound was prepared via the 
general procedure:  The crude product was purified by chromatography on silica (10% 
EtOAc/Hex) to give 1-(2-methoxyphenyl)ethanol (3b, 166 mg, 94%) as a clear oil: (J&W 
Scientific 30.0 m x 0.25 mm ID Cyclosil β, 120 oC (1 min hold) to 130o @ 1o/min then 165o @ 
2o/min) found peaks at 17.86 (97.2%, (R)-3b) and 18.78 (2.80%, (S)-3b); [α]D25 = +62.1 (c = 0.83, 
EtOH) (lit.5 [α]D25 = -64.3 (99% ee (S)) (c = 1.04, EtOH)); 1H NMR (400 MHz, CDCl3) δ 7.54 
(1H, d, J = 7.5 Hz), 7.27 (1H, t, J = 6.4 Hz), 7.23-7.15 (2H, m), 5.16 (1H, q, J = 6.4 Hz), 2.37 
(3H, s) 1.49 ppm (3H, d, J = 6.4 Hz); 13C NMR (100 MHz, CDCl3) δ 143.9, 134.2, 130.4, 127.2, 
126.4, 124.5, 66.8, 23.9, 18.9 ppm. 
 
 (R)-1-(2-trifluoromethylphenyl)ethanol (3c).  The title compound was prepared via 
the general procedure.  The crude product was purified by chromatography on silica (10% 
EtOAc/Hex) to give 1-(2-trifluoromethylphenyl)ethanol (3c, 202 mg, 82%) as a clear oil: (J&W 
Scientific 30.0 m x 0.25 mm ID Cyclosil β, 120 oC (1 min hold) to 130o @ 1o/min then 165o @ 
2o/min) found peaks at 17.86 (95.6%, (R)-3c) and 18.78 (4.40%, (S)-3c) ; [α]D25 = +25.8 (c = 1.0, 
                                                  
4 Y.-J. Cherng, J.-M. Fang, T.-J. Lu, J. Org. Chem. 1999, 64, 3207-3212. 
5 K. Nakamura, T. Matsuda, J. Org. Chem. 1998, 63, 8957-8964. 
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MeOH) (lit. [α]D22 = -28.4 (99% ee (S)) (c = 1.26, MeOH)); 1H NMR (400 MHz, CDCl3) δ 7.85 
(1H, d, J = 7.8 Hz), 7.64-7.60 (2H, m), 7.39 (2H, 1H, t, J = 6.4 Hz), 5.36 (1H, q, J = 5.6, 1.0 Hz), 
1.51 ppm (3H, d, J = 6.3 Hz); 13C NMR (100 MHz, CDCl3) δ 145.1, 132.3, 127.3, 127.1 , 126.4 
(d, JCF = 30.2 Hz), 125.2 (q, JCF = 5.8 Hz), 124.4 (d, JCF = 273.8 Hz), 65.6 (d, JCF = 2.2 Hz), 25.4 
ppm. 
 
 (R)-1-(2-chlorophenyl)ethanol (3d).  The title compound was prepared via the 
general procedure:  The crude product was purified by chromatography on silica (10% 
EtOAc/Hex) to give 1-(2-chlorophenyl)ethanol (3d, 193 mg, 95%) as a clear oil: (J&W Scientific 
30.0 m x 0.25 mm ID Cyclosil β, 120 oC (1 min hold) to 130o @ 1o/min then 165o @ 2o/min) 
found peaks at 21.52 (96.4%, (R)-3d) and 24.77 (3.6%, (S)-3d); [α]D25 = +60.3 (c = 1.0, CHCl3) 
(lit. [α]D25 = -62.7 (99% ee (S)) (c = 0.894, CHCl3)); 1H NMR (400 MHz, CDCl3) δ 7.60 (1H, dd, 
J = 7.7, 1.6 Hz), 7.35-7.28 (2H, m), 7.20 (1H, td, J = 7.7, 1.6 Hz), 5.28 (1H, q, J = 6.3, 2.8 Hz), 
2.37 (3H, s) 1.49 ppm (3H, d, J = 6.5 Hz); 13C NMR (100 MHz, CDCl3) δ 143.1, 131.6, 129.4, 
128.4, 127.2, 126.4, 66.9, 23.5 ppm. 
 
 (R)-1-(2-fluorophenyl)ethanol (3e).  The crude product was purified by 
chromatography on silica (10% EtOAc/Hex) to give 1-(2-fluorophenyl)ethanol (3e, 158 mg, 
87%) as a clear oil: (J&W Scientific 30.0 m x 0.25 mm ID Cyclosil β, 120 oC (1 min hold) to 
130o @ 1o/min then 165o @ 2o/min) found peaks at 17.86 (95.3%, (R)-3e) and 18.78 (4.70%, 
(S)-3e); [α]D25 = +39.8 (c = 0.5, MeOH) (lit. [α]D25 = -44.5 (99% ee (S)) (c = 0.782, MeOH)); 1H 
NMR (400 MHz, CDCl3) δ 7.50 (1H, t, J = 5.8 Hz), 7.28-7.24 (1H, m), 7.17 (1H, t, J = 7.5 Hz), 
7.07-7.02 (1H, m), 5.24 (1H, dq, J = 6.9, 2.5 Hz), 2.37 (3H, s) 1.54 ppm (3H, d, J = 6.5 Hz); 13C 
NMR (100 MHz, CDCl3) δ 159.7 (d, JCF = 254.3 Hz), 132.7 (d, JCF = 13.3 Hz), 128.7 (d, JCF = 
8.2 Hz), 126.6 (d, JCF = 4.5 Hz), 124.3 (d, JCF = 3.4 Hz), 115.2 (d, JCF = 1.8 Hz), 64.3 (d, JCF = 
3.1 Hz), 24.0 ppm. 
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